Kevin Davis Email & Phone Number

New York City Metropolitan Area And New Jersey

Oncology Account Manager (Manhattan, Westchester/Hudson Valley, Brooklyn, Bronx, Queens, Long Island, Connecticut, New Jersey)

New York City Metropolitan Area, New York State, Connecticut

• Achieved 122.0% to goal for Sylvant.
• Presently performing at 379 Units QTD.
• Enacted sustainable relationships with HCP’s and leveraged customer insights to develop strategic solutions in Ultra Rare Disease Market.

New York City Metropolitan Area, Connecticut

• Leading district with 147.9% with Bavencio.
• Formulary achievement in Top 10 Hospital for Bavencio.
• Implemented early adoption of Bavencio in Top 5 Accounts.

Bronx, Northern Westchester County, Yonkers

• Leading district with 121.1% with lead product Neulasta OnPro and Vectibix at 140.3%.
• Launched first Oncology Therapeutic Biosimilar MVASI.
• Drove adoption of Biosimilar MVASI in top accounts.
• Formulary achievement for lead product Neulasta OnPro due by first quarter in targeted account.

Greater New York City Area

• Achieved 102% with lead product Jadenu.
• Awarded Promacta Top 10 Territory in Country.
• Supported drive in early adoption of CAR-T Therapy with Kymriah.
• Recognized for Team Collaboration between NJ and NYC.
• Selected as Hematology Specialist for Washington DC NMA Convention.

Greater New York City Area

• Ranked Top 10% in performance for Butrans.
• Exceeding Territory Performance Attainment at 110% for OxyContin and 110% for Butrans.
• Q4 2015 OxyContin prescription performance #51 Nationally out of 530.
• Leading the NYC District Q3 2015 with 110 % in Product Class.
• Fiscal Year 2014 Ranked 97 out of 525.
• 2014 Northeast Region Top Performer in growth for OxyContin and Butrans.

Greater New York City Area

• Served as Interim District Manager for the Manhattan District, including planning/facilitating district meetings, and conducting/documenting field sessions with representatives.
• Ranked #3 in Manhattan District and #8 in the Northeast Region, with a Product Index of 105.6%.
• Achieved exclusive formulary status for Aciphex in second-largest account, one of the first formulary wins for Aciphex in the nation.
• Selected as an Advisor for the Initial Product Training Seminar on two occasions.
• Completed numerous field-training assignments and in-house training on Risperdal and Duragesic.
• Completed the Skills Development Seminar, the Train-the-Trainers Seminar, and the Focused Selection and Interviewing Workshop.

Greater New York City Area

• Awarded Manhattan District Sales Achievement Award.
• Consistent top performer within Manhattan District, achieving a Product Index of 121.69% at time of promotion and ranked #1 in District and #7 in nation.
• Featured in Janssen World Magazine.